NewsRegulatory & legal
Supplement rules in 2026: four changes worth knowing about
A reorganised FDA office, a planned rule on "generally recognized as safe" ingredients, a debate over what counts as a dietary ingredient, and tougher action on health claims. What is changing in US supplement regulation this year, in plain language.
What happened
Supplement regulation in the US doesn't change often, but 2026 has been a busy year. Four developments stand out.
- A new home for supplements at the FDA. The FDA's Office of Dietary Supplement Programs now sits inside a newly created Office of Food Chemical Safety, Dietary Supplements & Innovation, part of the agency's Human Foods Program.
- A planned rule on "GRAS" ingredients. Companies can currently decide for themselves that an ingredient is "generally recognized as safe" (GRAS) without telling the FDA. In March 2025, Health Secretary Robert F. Kennedy Jr. asked the FDA to look at ending that practice. The federal regulatory agenda published in July 2026 lists a proposed rule that would make GRAS notices to the FDA mandatory for certain substances and create a public inventory of them. It is tentatively due in December 2026. The rule covers food substances, so its effect on supplements depends on the final wording.
- What counts as a "dietary ingredient". At a public meeting in March 2026, the FDA asked whether its definition should be updated for newer ingredients, such as those made by precision fermentation or cell culture.
- Tougher action on health claims. The Federal Trade Commission has been targeting supplement claims about weight loss, mental performance and mood, including claims made through influencers. In June 2026 it sued Amare Global, alleging that the company claimed its products could treat depression, anxiety and ADHD, including in children, without proof. The company has not been found liable; the case is ongoing.
Meanwhile in Congress, the Dietary Supplement Listing Act would require companies to list every product with the FDA. (We explain it here.)
Why it matters
In the US, supplements don't need approval before they are sold, and the FDA mostly acts after a problem appears. That puts more weight on the rules about what goes into a product (which is where GRAS and the definition of a dietary ingredient come in) and what a company is allowed to claim (which is the FTC's job). Supplements are not allowed to claim to treat, cure or prevent a disease. Claims that they do are a red flag.
What it means for you
- Be wary of any supplement that promises to treat a condition, such as depression, anxiety, ADHD or menopause itself. Legally, supplements can't make those claims.
- "Clinically proven" or "doctor recommended" on a label is a marketing phrase, not an FDA finding. Ask which study, in whom, and at what dose.
- If an ingredient is new to you, it is fair to ask your pharmacist whether it has a track record of safe use.
- Report side effects through the FDA's MedWatch, and misleading ads to the FTC at ReportFraud.ftc.gov.
Sources
- NutraIngredients, "Mid-year 2026: Regulatory updates from the US supplement industry" (17 July 2026)
- FTC, "FTC Sues to Stop Amare Global Holdings from Misrepresenting Health Benefits of its Dietary Supplements for Children" (June 2026)
- FDA MedWatch: report a problem
We summarise news in our own words and link to the original reporting and the primary sources. This is general information, not medical advice. Talk to your doctor before starting or changing any supplement.